Literature DB >> 25111856

Risks and effectiveness of compounded bioidentical hormone therapy: a case series.

Ruth Davis1, Pelin Batur, Holly L Thacker.   

Abstract

After the publication of the Women's Health Initiative, attitudes towards management of menopausal symptoms changed dramatically. One alternative that has received much media attention is the use of bioidentical hormone therapy (BHT). The media and celebrity endorsements have promoted a number of misconceptions about the risks and benefits associated with the various forms of BHT. This article will review the available evidence regarding the safety and efficacy of BHT in comparison to conventional hormone therapy. We will also review several cases seen in our midlife women's referral clinics, which demonstrate concerns for the safety and efficacy of BHT, including unexplained endometrial cancer in otherwise healthy BHT users. Due to the lack of sufficient data to support the efficacy or safety of BHT, we recommend the use of United States Food and Drug Administration-approved regimens in the management of menopausal symptoms.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25111856     DOI: 10.1089/jwh.2014.4770

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  8 in total

Review 1.  Update on primary ovarian insufficiency.

Authors:  Meghan Hewlett; Shruthi Mahalingaiah
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-12       Impact factor: 3.243

Review 2.  State of the evidence 2017: an update on the connection between breast cancer and the environment.

Authors:  Janet M Gray; Sharima Rasanayagam; Connie Engel; Jeanne Rizzo
Journal:  Environ Health       Date:  2017-09-02       Impact factor: 5.984

3.  Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.

Authors:  Ginger D Constantine; Dennis A Revicki; Risa Kagan; James A Simon; Shelli Graham; Brian Bernick; Sebastian Mirkin
Journal:  Menopause       Date:  2019-05       Impact factor: 2.953

4.  Determination of estradiol and progesterone content in capsules and creams from compounding pharmacies.

Authors:  Frank Z Stanczyk; Chunying Niu; Colleen Azen; Sebastian Mirkin; Julia M Amadio
Journal:  Menopause       Date:  2019-09       Impact factor: 2.953

Review 5.  Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy.

Authors:  JoAnn V Pinkerton; James H Pickar
Journal:  Menopause       Date:  2016-02       Impact factor: 2.953

6.  Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making.

Authors:  Jennifer Jo Thompson; Cheryl Ritenbaugh; Mark Nichter
Journal:  BMC Womens Health       Date:  2017-10-02       Impact factor: 2.809

7.  Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.

Authors:  James A Simon; Andrew M Kaunitz; Robin Kroll; Shelli Graham; Brian Bernick; Sebastian Mirkin
Journal:  Menopause       Date:  2019-05       Impact factor: 2.953

8.  Increased Incidence of Endometrial Cancer Following the Women's Health Initiative: An Assessment of Risk Factors.

Authors:  Ginger D Constantine; Grant Kessler; Shelli Graham; Steven R Goldstein
Journal:  J Womens Health (Larchmt)       Date:  2018-11-28       Impact factor: 2.681

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.